Read the latest news and views from Lymphoma Action. 

Use the drop down filter to find the most relevant news for you.

MHRA logo

New treatment approval for relapsed or refractory DLBCL

The UK’s Medicines & Healthcare products Regulatory Agency (MHRA) has approved tafasitamab, combined with lenalidomide, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who can’t have a stem cell transplant.

4 January 2022
Merry Christmas purple background

Season's Greetings!

Thank you for your support during 2021 - we're sending best wishes for the coming year. 

22 December 2021